Lead optimisation of OXS007417: in vivo PK profile and hERG liability modulation to optimise a small molecule differentiation agent for the potential treatment of acute myeloid leukaemia. (2024)
Attributed to:
The Epigenetic Control of Gene Expression in Leukaemia and Haematopoiesis
funded by
MRC
Abstract
No abstract provided
Bibliographic Information
Digital Object Identifier: http://dx.doi.org/10.1039/d4md00275j
PubMed Identifier: 39220761
Publication URI: http://europepmc.org/abstract/MED/39220761
Type: Journal Article/Review
Volume: 15
Parent Publication: RSC medicinal chemistry
Issue: 10
ISSN: 2632-8682